Unknown

Dataset Information

Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.


ABSTRACT:

Background

Sickle cell disease (SCD) and its complications contribute to high rates of morbidity and early mortality and high cost in the United States and African heritage community.

Objective

To evaluate the cost-effectiveness of gene therapy for SCD and its value-based prices (VBPs).

Design

Comparative modeling analysis across 2 independently developed simulation models (University of Washington Model for Economic Analysis of Sickle Cell Cure [UW-MEASURE] and Fred Hutchinson Institute Sickle Cell Disease Outcomes Research and Economics Model [FH-HISCORE]) using the same databases.

Data sources

Centers for Medicare & Medicaid Services claims data, 2008 to 2016; published literature.

Target population

Persons eligible for gene therapy.

Time horizon</

SUBMITTER: Basu A 

PROVIDER: S-EPMC11657757 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature